Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 23, 2026, 4:31 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Half-Normal Saline Clear all
Completed Not applicable Interventional

Adductor Canal Blocks With Bupivacaine and Magnesium After Same-day Discharge Total Knee Arthroplasty Improve Post-operative Pain Relief and Decrease Opioid Consumption: a Prospective Randomized Controlled Trial

NCT05004636
View directory record Official record
Conditions
Post-operative Pain, Acute
Interventions
Adding Magnesium as an adjuvant to the adductor canal Block (ACB) for same-day discharge total knee arthroplasty
Drug
Lead sponsor
Wayne State University
Other
Eligibility
18 Years to 100 Years
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Pontiac, Michigan
Source: ClinicalTrials.gov public record
Updated Aug 12, 2021 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 1 Interventional

Superselective Administration of VErapamil During Recanalization in Acute Ischemic Stroke

NCT02235558
View directory record Official record
Conditions
Ischemic Stroke
Interventions
Verapamil
Drug
Lead sponsor
Justin Fraser
Other
Eligibility
21 Years to 85 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
1
States / cities
Lexington, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 22, 2017 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Early Administration of ATG Followed by Cyclophosphamide, Busulfan and Fludarabine Before a Donor Stem Cell Transplant in Patients With Hematological Cancer

NCT00787761
View directory record Official record
Conditions
Myeloproliferative Disorders, Kidney Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Diseases
Interventions
anti-thymocyte globulin, busulfan, cyclophosphamide, fludarabine phosphate, methotrexate, tacrolimus, nonmyeloablative allogeneic HSCT
Biological · Drug · Procedure
Lead sponsor
Northside Hospital, Inc.
Other
Eligibility
Up to 75 Years
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Sep 30, 2012 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 4 Interventional Accepts healthy volunteers Results available

IV Acetaminophen for Post-Operative Pain Management in Enhanced Recovery After Surgery (ERAS) Population

NCT03198871
View directory record Official record
Conditions
Abdominal Wall Hernia, Pancreatic Diseases, Bowel Disease, Gastric Disease
Interventions
Acetaminophen Injectable Product, Sodium Chloride 0.9%, Intravenous
Drug
Lead sponsor
Kathirvel Subramaniam
Other
Eligibility
18 Years and older
Enrollment
180 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 27, 2021 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2Phase 3 Interventional Results available

Bradykinin Receptor Antagonism During Cardiopulmonary Bypass

NCT00223704
View directory record Official record
Conditions
Cardiopulmonary Bypass, Inflammation, Fibrinolysis, Surgery
Interventions
HOE 140, Aminocaproic Acid, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 80 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2012
U.S. locations
2
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 24, 2013 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 2 Interventional Results available

Persistent Methicillin Resistant Staphylococcus Aureus Eradication Protocol (PMEP)

NCT01594827
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Inhaled Vancomycin, Placebo (Sterile Water), Rifampin, Trimethoprim/Sulfamethoxazole (TMP/SMX), Doxycycline, Mupirocin Intranasal Creme, 4% chlorhexidine gluconate liquid skin cleanser
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
12 Years and older
Enrollment
29 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2017
U.S. locations
2
States / cities
Baltimore, Maryland • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Feb 25, 2019 · Synced Sep 23, 2026, 4:31 AM EDT
Withdrawn Phase 2 Interventional Accepts healthy volunteers

Restylane Silk for Treatment of Chest Wrinkles

NCT03324997
View directory record Official record
Conditions
Wrinkle
Interventions
Restylane Silk, Saline, Optical Coherence Tomography
Drug · Device
Lead sponsor
Heidi Waldorf
Other
Eligibility
25 Years to 55 Years · Female only
Healthy volunteers
Accepts healthy volunteers
Timeline
2018
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Mar 5, 2018 · Synced Sep 23, 2026, 4:31 AM EDT
Not yet recruiting Not applicable Interventional

Combination Versus Alone Liposomal Bupivacaine Blocks in Minimally Invasive Thoracic Surgery-1

NCT07254650
View directory record Official record
Conditions
Lung Cancer (Diagnosis)
Interventions
Arm 1 "LipoB-I": Liposomal Bupivacaine via Multi-Level Intercostal Nerve Block, Arm 2 "LipoB-S": Liposomal Bupivacaine via Serratus Anterior Plane Block, Arm 3 "LipoB-C": Liposomal Bupivacaine Administered via Combination Block
Procedure
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Aug 25, 2026 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

Spread of PrabotulinumtoxinA-xvfs Versus OnabotulinumtoxinA in the Treatment of Forehead Rhytides

NCT05807412
View directory record Official record
Conditions
Rhytides
Interventions
PrabotulinumtoxinA-Xvfs, OnabotulinumtoxinA
Drug
Lead sponsor
Lupo Center for Aesthetic and General Dermatology
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2024
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Mar 12, 2024 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

PTH And Calcium Responses to Exercise in Older Adults Experiment 2 (PACE Sr. 2)

NCT02580604
View directory record Official record
Conditions
Osteoporosis
Interventions
Calcium Chloride/Calcium Gluconate, Half-Normal Saline
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
60 Years to 80 Years · Female only
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2025
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Aug 12, 2025 · Synced Sep 23, 2026, 4:31 AM EDT
Not listed Phase 1 Interventional Accepts healthy volunteers

Efficacy and Safety Of AGE ZERO™ EXOSOMES To Treat Men and Women With Androgenetic Alopecia

NCT06482541
View directory record Official record
Conditions
Androgenetic Alopecia
Interventions
5 billion exosomes and saline solution microneedling, 50 billion exosomes and saline solution microneedling
Combination Product
Lead sponsor
Levit Dermatology
Other
Eligibility
18 Years and older
Enrollment
100 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Brooklyn, New York
Source: ClinicalTrials.gov public record
Updated Jul 15, 2024 · Synced Sep 23, 2026, 4:31 AM EDT
Not yet recruiting Phase 4 Interventional

Epoprostenol Plus Conventional Therapy in COld and Frostbite Injury (ECCO)

NCT07424378
View directory record Official record
Conditions
Frostbite
Interventions
Standard of care plus Epoprostenol infusion for 8 hours (hrs) per day up to 5 days maximum, Standard of Care + Placebo (Normal Saline)infusion for 8 hours per day up to 5 days maximum
Drug
Lead sponsor
University of Colorado, Denver
Other
Eligibility
18 Years and older
Enrollment
66 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Aurora, Colorado
Source: ClinicalTrials.gov public record
Updated Feb 19, 2026 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

Study of CD388 Intramuscular or Subcutaneous Administration in Healthy Subjects

NCT05285137
View directory record Official record
Conditions
Healthy
Interventions
CD388 Injection, Saline placebo
Combination Product · Drug
Lead sponsor
Cidara Therapeutics Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 65 Years
Enrollment
77 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 26, 2025 · Synced Sep 23, 2026, 4:31 AM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

A Prospective Randomized Double Blinded Controlled Trial of Non-Operative Management of TFCC Injuries

NCT03830775
View directory record Official record
Conditions
Wrist Injuries, PRP
Interventions
Platelet-rich plasma (PRP)
Procedure
Lead sponsor
Edna Rath
Federal
Eligibility
Not listed
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Sep 24, 2025 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 4 Interventional Results available

Study of EXPAREL in Patients Undergoing Breast Augmentation

NCT01582490
View directory record Official record
Conditions
Mammoplasty, Postoperative Pain
Interventions
Instillation - EXPAREL, Infiltration - EXPAREL
Drug
Lead sponsor
Pacira Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 75 Years · Female only
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Brighton, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 1, 2014 · Synced Sep 23, 2026, 4:31 AM EDT
Terminated Phase 4 Interventional Results available

IV Lidocaine in Pediatric AIS

NCT03893318
View directory record Official record
Conditions
Systemic Lidocaine Improves Pain Control After Surgery by Attenuating the Systemic Inflammatory Response to Surgery
Interventions
IV lidocaine, Placebos
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
12 Years to 18 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2024
U.S. locations
1
States / cities
St Louis, Missouri
Source: ClinicalTrials.gov public record
Updated Nov 11, 2025 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Treat COVID-19 Patients With Regadenoson

NCT04606069
View directory record Official record
Conditions
COVID-19, Lung Inflammation
Interventions
Regadenoson, Placebo Control
Drug · Other
Lead sponsor
University of Maryland, Baltimore
Other
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Mar 19, 2025 · Synced Sep 23, 2026, 4:31 AM EDT
Recruiting Phase 2 Interventional Accepts healthy volunteers

Effect of TXA on Reducing Bruising After Filler Injection

NCT06665594
View directory record Official record
Conditions
Facial Filler Injections, Hyaluronic Acid, Tranexamic Acid
Interventions
Hyaluronic Acid (HA), Tranexamic Acid (TXA), Saline (placebo)
Procedure · Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years to 89 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2026
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jul 22, 2026 · Synced Sep 23, 2026, 4:31 AM EDT
Terminated Not applicable Interventional Results available

Glycemic Effects of Morning Only, Evening Only or Twice Daily Insulin Glargine in Patients With Type 1 Diabetes

NCT00869414
View directory record Official record
Conditions
Type 1 Diabetes, Hypoglycemia
Interventions
Evening only administration of insulin glargine, Morning only administration of insulin glargine, split dose insulin glargine
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 90 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 28, 2017 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 3 Interventional Results available

Comparison of Sternal Wound Infiltration With Liposomal Bupivacaine v. Bupivacaine Hydrochloride

NCT03270514
View directory record Official record
Conditions
Coronary Artery Disease, Coronary Artery Stenoses, Valve Regurgitation, Mitral, Valve Regurgitation, Tricuspid
Interventions
Exparel Injectable Product, Bupivacaine Hydrochloride
Drug
Lead sponsor
Kathirvel Subramaniam
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
1
States / cities
Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Sep 4, 2021 · Synced Sep 23, 2026, 4:31 AM EDT
Suspended Not applicable Interventional

Half-normal Saline in Idiopathic Left Ventricular Outflow Tract Arrhythmias Ablation

NCT03502499
View directory record Official record
Conditions
Ventricular Arrythmia
Interventions
Half-normal saline, Normal saline
Drug
Lead sponsor
Texas Cardiac Arrhythmia Research Foundation
Other
Eligibility
18 Years to 75 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
2
States / cities
Aurora, Colorado • Austin, Texas
Source: ClinicalTrials.gov public record
Updated Apr 10, 2022 · Synced Sep 23, 2026, 4:31 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

DPP4 Inhibition & Beta Cell Function

NCT02683187
View directory record Official record
Conditions
Healthy
Interventions
Active Comparator: Sitagliptin, Placebo Comparator - No Sitagliptin
Drug
Lead sponsor
David D'Alessio, M.D.
Other
Eligibility
35 Years to 70 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated May 2, 2021 · Synced Sep 23, 2026, 4:31 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Trial of PfSPZ Vaccine in Healthy Adults to Determine Safety, Tolerability and Efficacy Against Heterologous CHMI

NCT05604521
View directory record Official record
Conditions
Malaria, Malaria,Falciparum
Interventions
PfSPZ Vaccine, PfSPZ Challenge (7G8), Normal Saline
Biological · Other
Lead sponsor
Sanaria Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 24, 2024 · Synced Sep 23, 2026, 4:31 AM EDT
Recruiting Phase 2 Interventional

PEP-CMV Vaccine Targeting CMV Antigen to Treat Newly Diagnosed Pediatric HGG and DIPG and Recurrent Medulloblastoma

NCT05096481
View directory record Official record
Conditions
High Grade Glioma, Diffuse Intrinsic Pontine Glioma, Recurrent Medulloblastoma
Interventions
PEP-CMV, Temozolomide, Tetanus Diphtheria Vaccine
Biological · Drug
Lead sponsor
Nationwide Children's Hospital
Other
Eligibility
3 Years to 39 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
13
States / cities
Aurora, Colorado • Washington D.C., District of Columbia • Miami, Florida + 10 more
Source: ClinicalTrials.gov public record
Updated Aug 23, 2026 · Synced Sep 23, 2026, 4:31 AM EDT